Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02916056 · ClinicalTrials.gov registry record · Phase 3
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
A Phase 3 study, sponsored by vTv Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 297
- Enrollment target
NCT02916056 is a Phase 3 study that was terminated before completion, run by vTv Therapeutics. The registered enrollment target is 297 participants.
The verdict
NCT02916056, a Phase 3 study, was terminated before completion, sponsored by vTv Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 297 participants
- Enrollment target
Study Summary
This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
Interventions
- DRUG Azeliragon 5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02916056
The ClinicalTrials.gov registry entry for NCT02916056 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is vTv Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azeliragon 5mg is the first listed.
NCT02916056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02916056 about?
NCT02916056 is a clinical study titled "2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)". This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
What is the current status of trial NCT02916056?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 297 participants. The study started on 2016-12. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT02916056?
The interventions under investigation include: Azeliragon 5mg (DRUG).
Who is sponsoring clinical trial NCT02916056?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.